Detalle Publicación


Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Autores: Mateos, M. V. (Autor de correspondencia); Blacklock, H. ; Schjesvold, F. ; Oriol, A. ; Simpson, D.; George, A.; Goldschmidt, H. ; Larocca, A. ; Chanan-Khan, A. ; Sherbenou, D. ; Avivi, I. ; Benyamini, N. ; Iida, S.; Matsumoto, M. ; Suzuki, K. ; Ribrag, V.; Usmani, S. Z.; Jagannath, S.; Ocio, E. M. ; Rodríguez Otero, Paula; San Miguel Izquierdo, Jesús; Kher, U. ; Farooqui, M. ; Liao, J.; Marinello, P.; Lonial, S.; KEYNOTE-183 Investigators
Título de la revista: THE LANCET. HAEMATOLOGY
ISSN: 2352-3026
Volumen: 6
Número: 9
Páginas: e459 - e469
Fecha de publicación: 2019
ackground: Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed. KEYNOTE-183 assessed efficacy and safety of pomalidomide and dexamethasone with or without pembrolizumab in patients with relapsed or refractory multiple myeloma. Here, we present the findings of an unplanned, ad-hoc interim analysis at the request of the US Food and Drug Administration (FDA). Methods: KEYNOTE-183 was a randomised, open-label, phase 3 trial done at 97 medical centres across 11 countries (Australia, Canada, France, Germany, Israel, Italy, Japan, New Zealand, Norway, Spain, and USA). Patients aged at least 18 years with multiple myeloma, an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, previously treated with at least two lines of therapy (excluding pomalidomide) and refractory to the last line were randomly assigned 1:1 to the pembrolizumab plus pomalidomide and dexamethasone group or the pomalidomide and dexamethasone group via an interactive voice response or integrated web response system. Patients received oral pomalidomide 4 mg daily on days 1-21 and oral low-dose dexamethasone 40 mg on days 1, 8, 15, and 22 in 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The dual primary endpoints were progression-free survival and overall survival. Efficacy was assessed in all randomly assigned patients and safety was assessed in patients who received at leas